Autologous Chondrocyte Implantation (ACI) for Cartilage Defects of the knee using Novocart® 3D and Novocart® Inject

Elsevier

Available online 8 September 2022, 150959

Operative Techniques in Sports MedicineAbstract

Ever since autologous chondrocyte implantation (ACI) has been introduced, there have been important advancements and progress leading to a more reliable and more standardized application of this technology. While first-generation ACI followed the principle of a cell-suspension being injected under an autologous periosteum patch, second and third generation of ACI are characterized by the use of biomaterials, either using a cell-suspension (2nd generation) or a combination of cells and the biomaterial (3rd generation). Due to easier handling and improved clinical outcome, 3rd generation ACI has become the gold standard for the use of ACI at this time. The present chapter focuses on the Novocart® 3rd generation ACI products. While Novocart® 3D uses a collagen membrane and therefore a implantable biomaterial, Novocart® Inject is a hydrogel-based ACI product which can be injected into the cartilage defects. Both products are currently under way for central European market authorization by the European Medicinal Agency (EMA), additionally a FDA-approval trial is under way for Novocart® 3D. Products characteristics, indication, surgical technique and clinical outcome are summarized in the present chapter.

View full text

© 2022 Elsevier Inc. All rights reserved.

留言 (0)

沒有登入
gif